Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
106.6 USD -3.64% Intraday chart for Moderna, Inc. +3.38% +7.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
US Equity Markets Close Higher Wednesday Ahead of Q4 GDP Reading MT
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care Stocks Gain Wednesday Afternoon MT
Global markets live: Apple, UBS, Microstrategy, Merck, Amazon... Our Logo
Top Midday Stories: Disney, DeSantis Reach Settlement; Judge Allows SEC's Coinbase Lawsuit to Proceed; UBS Sells Credit Suisse Assets to Apollo; Online Betting Platforms Form Group to Tackle Problem Gambling; EU Rejects Amazon Bid to Suspend Advertising Clause; Moderna to Receive $750 Million from Blackstone; Merck Drug Gets FDA Approval MT
Focus on Waller, PCE and Powell Our Logo
Sector Update: Health Care Stocks Edge Higher Pre-Bell Wednesday MT
Transcript : Moderna, Inc. - Special Call
Wall St set to open higher as growth stocks recover RE
Moderna to Receive up to $750 Million From Blackstone to Fund Influenza Program MT
Moderna: presents advances in its mRNA pipeline CF
Blackstone to Fund Moderna's Flu Research With up to $750 Million DJ
Moderna gets $750 mln funding from Blackstone Life Sciences to develop flu shots RE
Sector Update: Health Care Stocks Steady Premarket Tuesday MT
Moderna Says New COVID-19 Vaccine Elicits Stronger Immune Response Than Spikevax in Phase 3 Trial MT
Moderna: promising results for new Covid vaccine CF
Moderna Says New COVID-19 Shot More Effective than Licensed Vaccine in Late-stage Study MT
Moderna Says New COVID-19 Shot More Effective than Licensed Vaccine in Late-stage Study MT
Moderna, Inc. Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine CI
Moderna, Inc. prepares for the post-Covid era Our Logo
Wall St ends higher as Fed sees three rate cuts RE
Wall St advances as US Fed keeps three rate cuts on the horizon RE
Transcript : Moderna, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:35 PM
Moderna, Merck to Begin Phase 2/3 Study of V940 Plus Pembrolizumab in Skin Cancer MT
Rovi explores sale of unit that makes drugs for third parties RE
Chart Moderna, Inc.
More charts
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
106.6 USD
Average target price
134.1 USD
Spread / Average Target
+25.86%
Consensus
  1. Stock
  2. Equities
  3. Stock Moderna, Inc. - Nasdaq
  4. News Moderna, Inc.
  5. Swissmedic OKs Moderna's COVID-19 Jab For Children Aged Six To 11 Years